Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep has discontinued its multinational, randomized, double-blind Phase III TACTI-004 study in first-line non-small cell lung cancer after a pre-specified interim futility analysis showed the trial was unlikely to meet its endpoints. Management acknowledged the disappointment for shareholders, partners, and staff but emphasized that the broader pipeline remains intact, notably the differentiated IMP761 program with data expected in early June.
The company has initiated a root cause analysis of the TACTI-004 data to understand the drivers of the futility outcome and to guide future decisions across the eftilagimod alfa pipeline, a process that may extend into the third quarter of calendar 2026. Immutep reports ongoing, constructive discussions with partners and stakeholders and reiterates its focus on disciplined execution, value creation, and prudent capital management, with further market updates to follow as new data and analyses emerge.
The most recent analyst rating on (AU:IMM) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments, including its eftilagimod alfa (efti) program and the IMP761 asset. The company targets oncology and immune-related indications, working with global partners, investigators, and shareholders to advance a diversified clinical pipeline.
Average Trading Volume: 21,516,419
Technical Sentiment Signal: Sell
Current Market Cap: A$64.84M
Learn more about IMM stock on TipRanks’ Stock Analysis page.